What is Altimmune's G&A?

Altimmune (ALT) reported G&A of $8.05M in Q1 2026.

How has Altimmune's G&A changed year-over-year?

Altimmune's G&A increased by 34.4% year-over-year, from $5.99M to $8.05M.

What is the long-term trend for Altimmune's G&A?

Over 4 years (2021 to 2025), Altimmune's G&A has grown at a 16.2% compound annual growth rate (CAGR), from $15.41M to $28.1M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Altimmune ALT G&A

G&A at other companies

Viking TherapeuticsVKTX

$13.98M-0.7%

Wave Life SciencesWVE

$22.1M+20.4%

MeiraGTx Holdings plcMGTX

$8.93M-4.7%

Alumis Inc.ALMS

$18.61M-16.5%

Beam TherapeuticsBEAM

$34.43M+23.2%

Protagonist TherapeuticsPTGX

$13.28M+13.1%

Other financials

Income statement

See full

Revenue$26.0K+420%

Operating income-$24.2M-11.1%

Net income-$22.6M-15.3%

EPS (diluted)-$0.18+30.8%

Balance sheet

See full

Cash & equivalents$97.6M+98.7%

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

See full

Operating cash flow-$20.9M-24.4%

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation

See full

Market cap$558.14M-2.1%

Enterprise value$495.27M-5.0%

P/S13,613.2×-24,380×

Profitability

See full

Operating margin-230,461%-82,087pp

Net margin-214,861%-76,057pp

FCF margin-17,806.8%-110,030pp

Returns & leverage

See full

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Altimmune's G&A?: Altimmune (ALT) reported G&A of $8.05M in Q1 2026.
How has Altimmune's G&A changed year-over-year?: Altimmune's G&A increased by 34.4% year-over-year, from $5.99M to $8.05M.
What is the long-term trend for Altimmune's G&A?: Over 4 years (2021 to 2025), Altimmune's G&A has grown at a 16.2% compound annual growth rate (CAGR), from $15.41M to $28.1M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.